Who is sponsoring NCT04050319?

NCT04050319 is sponsored by ATI Holdings, LLC.

What drugs are being tested in NCT04050319?

Interventions in NCT04050319: Screening and diagnosis if injured.

What condition does NCT04050319 study?

NCT04050319 studies Sport Medicine.

Is NCT04050319 still recruiting?

NCT04050319 is currently enrolling by invitation. Last updated 8 August 2019.

Last reviewed 2019-08-08 · How we verify

NCT04050319

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ATI Evidence-based Guide Investigating Medical and Preventative Services

ENROLLING BY INVITATION Last updated 8 August 2019

What this trial tests

trial testing Screening and diagnosis if injured in Sport Medicine in 35,000 participants. Enrolling by invitation.

Timeline

1 August 2019

Primary endpoint
31 December 2025

31 December 2027

Quick facts

Lead sponsor	ATI Holdings, LLC
Status	ENROLLING BY INVITATION
Study type	OBSERVATIONAL
Enrollment	35,000
Start date	1 August 2019
Primary completion	31 December 2025
Estimated completion	31 December 2027
Sites	1 location across United States

Drugs / interventions tested

Screening and diagnosis if injured

Conditions studied

Sport Medicine — all drugs for Sport Medicine →

Sponsor

ATI Holdings, LLC — full company profile →

Who can join

Adults 12 to 25, any sex, with Sport Medicine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators goal is to provide a mechanism that allows for a better understanding of athlete management from injury prevention through maintenance of health or development of injury and rehabilitation. The goal is to describe best practice for prevention and treatment to maximize return to health, sport, and patient reported outcomes following time. This includes collection of pre-existing risk factors, prevention program participation, treatment initiatives, functional outcomes measured by standardized and validated tools from the published literature. It incorporates comorbidities and patient demographic characteristics. All of these components come together to form a remarkably comprehensive picture of athlete health, influencing factors, and their associated outcomes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Impact of Statewide Limitations of Practice on High School Injury Incidence During the COVID-19 Season: An Ecological Study.
Bullock G, Prats-Uribe A, Thigpen CA, Boyer L, et al · · 2022 · cited 5× · PMID 35766456 · DOI 10.1177/19417381221106693

Verify or expand the search:

Other ATI Holdings, LLC trials

Trials by the same sponsor.

NCT02285868 — ATI Evidence-based Guide Investigating Clinical Services · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04050319 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ATI Holdings, LLC
Last refreshed: 8 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04050319.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing